Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity ... obesity drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice president for development, said ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema ... Novo Nordisk's executive vice president for development, said on a call with analysts.

Last September, Novo Nordisk reported Phase 2 obesity study results showing ... said Wednesday that it is evaluating this drug for further clinical development in this indication.

Novo Nordisk’s main competitor is the American drugmaker Eli Lilly, which also sells obesity drugs. On Wednesday, Novo Nordisk said its revenue jumped 25 percent last year to 290 billion Danish ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

(Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next ...